Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Accounts Payables (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Accounts Payables for 16 consecutive years, with $11.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Accounts Payables rose 46.9% to $11.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $11.6 million, a 46.9% increase, with the full-year FY2024 number at $11.3 million, up 70.23% from a year prior.
  • Accounts Payables was $11.6 million for Q3 2025 at Plus Therapeutics, up from $6.4 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $11.6 million in Q3 2025 to a low of $1.6 million in Q2 2021.
  • A 5-year average of $6.3 million and a median of $6.5 million in 2023 define the central range for Accounts Payables.
  • Peak YoY movement for Accounts Payables: crashed 55.4% in 2021, then soared 226.85% in 2022.
  • Plus Therapeutics' Accounts Payables stood at $2.6 million in 2021, then skyrocketed by 218.02% to $8.4 million in 2022, then decreased by 20.72% to $6.6 million in 2023, then surged by 70.23% to $11.3 million in 2024, then rose by 2.97% to $11.6 million in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Accounts Payables are $11.6 million (Q3 2025), $6.4 million (Q2 2025), and $9.2 million (Q1 2025).